Chronic spontaneous urticaria

CSPC develops, produces and sells its own innovative drugs. Its growth has been sluggish over the past three years due to a slowdown for its finished drug business.

FAST NEWS: CSPC Pharma’s urticaria drug approved in China

The Latest: CSPC Pharmaceutical Group Ltd. (1093.HK) announced on Tuesday that its chronic spontaneous urticaria treatment, Omalizumab for Injection, has been approved for sale in China by the country’s National Medical Products Administration…
1093.HK

Recent Articles

RELATED ARTICLES

  1. Liu Yongjun’s experience in the commercialization of innovative drugs and his connections with multinational pharmaceutical companies are urgently needed for CSPC Pharmaceutical’s ongoing transformation.
    CSPC Pharma taps R&D superstar in quest for new breakout drugs
    1093.HK
  2. CSPC Pharma weighs up diet drug for bigger bottom line
    1093.HK
  3. Novel drugs lift Sino Biopharm earnings, easing price-cap pain
    1177.HK
  4. Profit setback for Simcere Pharma in novel drugs quest
    2096.HK
  5. Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
    1952.HK
  6. BeiGene still bleeding red ink despite blockbuster drug
    BGNE.US 6160.HK 688235.SHG
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva